Antipsychotic use in children and adolescents: A 1-year follow-up study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 5, 2014, Pages 613-619

  Baeza, Inmaculada ^a,b   De La Serna, Elena ^a,b   Calvo Escalona, Rosa ^a,b   Morer, Astrid ^a,b   Merchán Naranjo, Jessica ^c   Tapia, Cecilia ^c   Martínez Cantarero, Ma Carmen ^d   Andrés, Patrícia ^d   Alda, José A ^e   Sánchez, Bernardo ^e   Arango, Celso ^c   Castro Fornieles, Josefina ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Section of Child and Adolescent Psychiatry and Psychology Hospital Infantil Universitario Niño Jesú S   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

adolescents; antipsychotics; children; diagnosis

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE;

ADOLESCENT; ARTICLE; BIPOLAR DISORDER; CHILD; CHILD PSYCHIATRY; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG USE; EATING DISORDER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; CLINICAL PRACTICE; MENTAL DISORDERS; PRESCHOOL CHILD; SPAIN; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; POLYPHARMACY; PRACTICE PATTERNS, PHYSICIANS'; SPAIN;

EID: 84907012146     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000190     Document Type: Article

References (46)

1. Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother. 2006;40:205-211.
2. Kalverdijk LJ, Tobi H, Van den Berg PB, et al. Use of antipsychotic drugs among dutch youths between 1997 and 2005. Psychiatr Serv. 2008;59:554-560.
3. Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69:1247-1256.
4. Sourander A, Ellilä H, Välimäki M, et al. Psychopharmacological treatment of child and adolescent psychiatric inpatients in Finland. J Child Adol Psychopharmacol. 2002;12:147-155.
5. Gilat Y, Ben-Dor DH, Magen A, et al. Trends in prescribing of psychotropic medications for inpatients adolescents in Israel: a 10 years retrospective analysis. Eur Psychiatry. 2011;26:265-269.
6. Constantine RJ, Boaz T, Tandon R. Antipsychotic polipharmacy in the treatment of children and adolescents in the fee-for service component of a large state Medicaid program. Clin Ther. 2010;32:949-959.
7. Pathak P, West D, Martin BC, et al. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61:123-129.
8. Winterfeld U, Le Heuzey MF, Acquaviva E, et al. Off-label use of psychotropic medications in pediatric wards: a prospective study. Arch Pediatr. 2009;16:1252-1260.
9. Winterfeld U, Le Heuzey MF, Acquaviva E, et al. Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital. Pharm World Sci. 2008;30:600-604.
10. Zoëga H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adol Psychopharmacology. 2009;19:757-764.
11. Pejovic-Milovancevic M, Miletic V, Popovic-Deusic S, et al. Psychotropic medication use in children and adolescents in an inpatient setting. Psychiatriki. 2011;22:314-319.
12. Clavenna A, Andretta M, Pilati P, et al. Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatr. 2011;11:40.
13. Castro-Fornieles J, Parellada MJ, Gonzalez-Pinto A, et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adol Psychopharmacology. 2008;18: 327-336.
14. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011:25:383-399.
15. Noguera A, Ballesta P, Baeza I, et al. Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol. 2013;33:463-471.
16. Merchan-Naranjo J, Tapia C, Bailón C, et al. Secondary effects of antipsychotic treatment in naBve or quasi-naBve children and adolescents: design of a follow-up protocol and baseline results. Rev Psiquiatr Salud Ment. 2012;5:217-228.
17. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6: 79-83.
18. Almandil NB, Wong CK. Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed. 2011;96:192-196.
19. Spanish Drug Regulatory Agency. AEMPS: Agencia Española de Medicamentos y Productos Sanitarios. Available at: www.aemps.gob.es/cima/ fichastecnicas.do. Accessed October 14, 2013.
20. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
21. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12:116-141.
22. Findling RL, Johnson JL, MCClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum Study. J Am Acad Child Adol Psychiatry. 2010;49:583-594.
23. Albert PR. Drugs for kids: good or bad? J Psychiatry Neurosci. 2012;37:293-295.
24. Biederman J. Credibility crisis in paediatric psychiatry. Nat Neurosci. 2008;11:983.
25. Prinsheim T, Gorman D. Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiatry. 2012;57:722-727.
26. Buitelaar J, van der Gaag R, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239-248.
27. Synder R, Turgay A, Aman M, et al. Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorder in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;4:1026-1036.
28. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hiperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:558-565.
29. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509-516.
30. Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012;9:CD008559.
31. DelBello MP, Adler CM, Whitsel RM, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry. 2007;68:789-795.
32. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73:486-496.
33. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19(suppl 1):1-93.
34. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622-632.
35. Kishi T, Kafantaris V, Sunday S, et al. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 2012;73:e757-e766.
36. Patel NC, Crismon NL, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44:548-566.
37. Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006. Psychiatr Serv. 2008;59:547-553.
38. McClellan J, Stock S, the AACAP Committee on Quality Issues. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2013;52:976-990.
39. Findling RL, Frazier JA, Gerbino-Rosen G, et al. Is there a role for clozapine in the treatment of children and adolescents? J Am Acad Child Adolesc Psychiatry 2007;46:423-428.
40. Prinsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children. A systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34:651-668.
41. Zito JM, Safer DJ, Berg LTWJ, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adol Psychiatry Ment Health. 2008;2:26.
42. Toteja N, Gallego JA, Saito E, et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharmacol. 2013;14:1-11.
43. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18-28.
44. Paton C, Barnes TRE, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192:435-439.
45. Tsutsumi C, Uchida H, Suzuki T, et al. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr Res. 2011;130:40-46.
46. Bernardo M, Vieta E, Sáiz Ruiz J, et al. Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment. 2011;4:150-168.